Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Adjuvant treatment of colorectal cancer.

Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ.

CA Cancer J Clin. 2007 May-Jun;57(3):168-85. Review.

PMID:
17507442
2.

Systemic treatment of colorectal cancer.

Wolpin BM, Mayer RJ.

Gastroenterology. 2008 May;134(5):1296-310. doi: 10.1053/j.gastro.2008.02.098. Review.

3.

Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.

Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, Park JO, Kim SY, Kim TY, Kim JH, Ahn JB, Lim SB, Yu CS, Kim JC, Yun SH, Kim JH, Park JH, Park HC, Jung KH, Kim TW.

Lancet Oncol. 2014 Oct;15(11):1245-53. doi: 10.1016/S1470-2045(14)70377-8. Epub 2014 Sep 4.

PMID:
25201358
4.

Combined-modality therapy for rectal cancer: future prospects.

Czito BG, Willett CG, Bendell JC.

Clin Colorectal Cancer. 2007 Sep;6(9):625-33. Review.

PMID:
17945034
5.

Update: NCCN colon and rectal cancer clinical practice guidelines.

Kiel K, Engstrom PF.

J Natl Compr Canc Netw. 2004 Sep;2 Suppl 3:S-14-8. No abstract available.

PMID:
23570093
6.

Adjuvant chemotherapy for colon and rectal cancer.

Fuchs CS, Mayer RJ.

Semin Oncol. 1995 Oct;22(5):472-87. Review. No abstract available.

PMID:
7570058
7.

Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.

Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, Hofheinz RD, Ghadimi M, Wolff HA, Lang-Welzenbach M, Raab HR, Wittekind C, Ströbel P, Staib L, Wilhelm M, Grabenbauer GG, Hoffmanns H, Lindemann F, Schlenska-Lange A, Folprecht G, Sauer R, Liersch T; German Rectal Cancer Study Group..

Lancet Oncol. 2015 Aug;16(8):979-89. doi: 10.1016/S1470-2045(15)00159-X. Epub 2015 Jul 15.

PMID:
26189067
8.

Adjuvant therapy for stage II and III colorectal cancer.

de Gramont A, Tournigand C, André T, Larsen AK, Louvet C.

Semin Oncol. 2007 Apr;34(2 Suppl 1):S37-40.

PMID:
17449351
9.

An overview of approaches to adjuvant therapy for colorectal cancer in the United States.

Hobday TJ.

Clin Colorectal Cancer. 2005 Apr;5 Suppl 1:S11-8. Review.

PMID:
15871761
10.
11.

[Adjuvant chemotherapy for colorectal cancer in Japan-current state and problem areas].

Komatsu Y.

Gan To Kagaku Ryoho. 2007 May;34(5):799-807. Review. Japanese.

PMID:
17496461
12.
13.

Adjuvant therapy of colorectal cancer.

Kemeny N, Saltz L, Cohen A.

Surg Oncol Clin N Am. 1997 Oct;6(4):699-722. Review.

PMID:
9309089
14.

[Progression of adjuvant chemotherapy for colon cancer].

He YJ, Dong QM, Li YH.

Ai Zheng. 2005 Dec;24(12):1546-9. Review. Chinese.

PMID:
16351811
15.

Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.

Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, Reidy-Lagunes DL, Gollub MJ, Shia J, Guillem JG, Temple LK, Paty PB, Saltz LB.

J Clin Oncol. 2014 Feb 20;32(6):513-8. doi: 10.1200/JCO.2013.51.7904. Epub 2014 Jan 13.

PMID:
24419115
16.

Colorectal cancer.

Maghfoor I.

Lancet. 1999 Mar 20;353(9157):1013. No abstract available.

PMID:
10459936
17.

Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.

Liersch T, Langer C, Ghadimi BM, Kulle B, Aust DE, Baretton GB, Schwabe W, Häusler P, Becker H, Jakob C.

J Clin Oncol. 2006 Sep 1;24(25):4062-8.

PMID:
16943523
18.

Adjuvant Chemotherapy in Rectal Cancer after Chemoradiotherapy.

Boustani J, Caubet M, Bosset JF.

Clin Oncol (R Coll Radiol). 2016 Feb;28(2):140-5. doi: 10.1016/j.clon.2015.11.004. Epub 2015 Dec 14. Review.

PMID:
26698026
19.

Beyond 5-fluorouracil: the emerging role of newer chemotherapeutics and targeted agents with radiation therapy.

Czito BG, Willett CG.

Semin Radiat Oncol. 2011 Jul;21(3):203-11. doi: 10.1016/j.semradonc.2011.02.006. Review.

PMID:
21645865
20.

Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer.

Sastre J, Custodio A, Sanchez JC, Ortega L, Rodriguez L, Puente J, Corona J, Alfonso R, de las Heras M, Dıaz-Rubio E.

Anticancer Drugs. 2011 Feb;22(2):185-90.

PMID:
21218606

Supplemental Content

Support Center